SCHEMBL7000448

SCHEMBL7000448

CCOC(=O)c1c(Nc2cc(F)ccc2[N+](=O)[O-])sc2cc(C)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.43
ALDH1A1 P00352 9/20 0.39
RAB9A P51151 3/20 0.39
HPGD P15428 3/20 0.39
NPC1 O15118 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALPL P05186 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 3/20 0.38
PKM P14618 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
LMNA P02545 6/20 0.37
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
POLB P06746 3/20 0.37
GALR2 O43603 1/20 0.37
MITF O75030 1/20 0.37
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6990165 0.91 MAPT (0.38) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6996023 0.90 SMN1; SMN2 (0.43) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6993953 0.90 MAPT (0.41) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6990197 0.87 ALDH1A1 (0.43) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL7000921 0.85 MAPT (0.47) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6995665 0.84 MAPT (0.41) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6991782 0.83 ALDH1A1 (0.41) MAPTALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL6994728 0.82 KMT2A (0.43) MAPTALDH1A1RAB9AHPGDNPC1
SCHEMBL6992000 0.80 KMT2A (0.44) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL6991878 0.79 KMT2A (0.41) MAPTALDH1A1RAB9AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885ALDH1A1 366/4885RAB9A 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.